Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
Improving Sensorimotor Function in CIPN: A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of Transcranial Direct Current to the Sensorimotor Cortex
This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Eshaka Eshwar
- 电话号码:734-232-5901
- 邮箱:eshaka@med.umich.edu
学习地点
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan Rogel Cancer Center
-
首席研究员:
- Brendan L. McNeish
-
接触:
- Eshaka Eshwar
- 电话号码:734-232-5901
- 邮箱:eshaka@med.umich.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 18 to 85 years of age
- Diagnosis of cancer, stages I-IV
- Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)
- Presence of CIPN defined as new, length-dependent numbness, tingling, and/or pain that developed with neurotoxic chemotherapy
- CIPN20 score ≥ 20
- Able to walk unassisted
- Proficient in English
Exclusion Criteria:
- Known brain metastases
- Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)
- History of brain or spinal surgery
- Neuropathy other than CIPN
- Significant hearing or vision deficits
- Vestibulopathy
- Currently receiving chemotherapy, radiation therapy, or immunotherapy
- Contraindications to transcranial direct current stimulation (tDCS), including recent seizures
- Presence of metallic objects in the head
- Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)
- Active scalp dermatological conditions
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm I (active tDCS)
Patients undergo tDCS to the sensorimotor cortex, using the Starstim-8™ system, for 20 minutes. One week later, patients cross-over to Arm II. |
Ancillary studies Undergo tDCS
其他名称:
|
|
假比较器:Arm II (sham tDCS)
Patients undergo sham tDCS to the sensorimotor cortex, using the Starstim-8™ system, for 20 minutes. One week later, patients cross-over to Arm I. |
Ancillary studies Undergo sham tDCS
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Vibration detection threshold
大体时间:at weeks 2 and 3
|
Assessed via Vibration Detection Threshold (CASE IV): Quantitative sensory testing (QTS) for large fiber function. Will conduct a series of two-way analysis of variance (ANOVAs) with each of the vibratory thresholds, cold thresholds, and physical function measures as the dependent variables. Group (active transcranial direct current stimulation [tDCS] versus sham tDCS) and time (baseline, immediate post) will be included as fixed factors of interest along with their interaction to assess treatment effects over time. |
at weeks 2 and 3
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cold detection threshold
大体时间:at weeks 2 and 3
|
Assessed via Cold Detection Threshold (CASE IV): QST for small fiber function. Will conduct a series of two-way ANOVAs with each of the vibratory thresholds, cold thresholds, and physical function measures as the dependent variables. Group (active tDCS versus sham tDCS) and time (baseline, immediate post) will be included as fixed factors of interest along with their interaction to assess treatment effects over time. |
at weeks 2 and 3
|
|
Correlation between executive function and chemotherapy-induced peripheral neuropathy (CIPN) severity
大体时间:At baseline
|
Assessed with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20. Will use multivariable models with CIPN20 as the dependent variable, executive function as the primary predictor, and sural amplitude as a covariate. Additional covariates will include age, sex, depression, and pain. |
At baseline
|
合作者和调查者
调查人员
- 首席研究员:Brendan L McNeish、University of Michigan Rogel Cancer Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- UMCC 2025.097
- NCI-2026-03995 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- HUM00276508 (其他标识符:University of Michigan Rogel Cancer Center)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.